Shalender Bhasin, M.B., B.S.
Shalender Bhasin, M.D., B.S., is a Professor of Medicine at the Harvard Medical School, and Director of the Research Program for Men’s Health and Aging at the Brigham and Women’s Hospital in Boston, Mass. He is the co-Director of the Brigham Center for Transgender Health. He is also the Director of the Boston Claude D. Pepper Aging Research Center at the Harvard Medical School.
Dr. Bhasin is one of the foremost experts in men’s health and aging. He has published more than 400 original research papers in top tier journals and has conducted some of the most important randomized trials of testosterone in men and women. His lab has characterized the mechanisms of testosterone's action and the role of steroid 5-alpha reductase in adults. He led the Endocrine Society's expert panel that developed the guidelines for testosterone treatment of hypogonadal men since 2005. His lab has investigated the mechanisms of muscle loss with aging. He chaired an expert panel that developed the evidence-based definition of sarcopenia and has conducted many randomized trials of function promoting therapies. He has been investigating the role of Nicotinamide Adenine Dinucleotide (NAD) in aging biology and the potential applications of NAD augmentation to treat age-related diseases.
Dr. Bhasin has been the recipient of numerous research, teaching, and mentorship awards throughout his career. He received the Endocrine Society's Outstanding Clinical Investigator Award, and the American College of Endocrinology's Frontiers in Science Award.
Shalender Bhasin is the recipient of research grants from AbbVie, MIB and FPT. He is also a consultant with Novartis. All relevant financial relationships have been resolved.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:AbbVie, MIB and FPTDate added:01/27/2023Date updated:02/01/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:NovartisDate added:02/01/2023Date updated:02/01/2023